About Pregnancy-specific beta-1-glycoprotein 5
Pregnancy-specific beta-1-glycoprotein 5 (PSG5) is a protein
from Homo sapiens identified by UniProt accession
Q15238, 335 residues long.
MolForge cross-references it against 0 known binders and
99 disease associations.
Target properties
| Protein name | Pregnancy-specific beta-1-glycoprotein 5 |
|---|
| UniProt accession | Q15238 |
|---|
| Gene | PSG5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 335 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (99)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.40
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.18
- multiple myeloma · score 0.17
- thyroid gland adenocarcinoma · score 0.16
- head and neck squamous cell carcinoma · score 0.11
- anti-chlamydia trachomatis antibody measurement · score 0.08
- ringed hair disease · score 0.08
- Griscelli syndrome type 3 · score 0.08
- uncombable hair syndrome · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15238-F1 | alphafold | PREDICTED | 85.70 | — |
Amino-acid sequence (335 residues)
MGPLSAPPCT QHITWKGLLL TASLLNFWNL PITAQVTIEA LPPKVSEGKD VLLLVHNLPQ NLAGYIWYKG QLMDLYHYIT SYVVDGQINI YGPAYTGRET VYSNASLLIQ NVTREDAGSY TLHIIKRGDR TRGVTGYFTF NLYLKLPKPY ITINNSKPRE NKDVLAFTCE PKSENYTYIW WLNGQSLPVS PRVKRPIENR ILILPSVTRN ETGPYECEIR DRDGGMRSDP VTLNVLYGPD LPSIYPSFTY YRSGENLYLS CFAESNPPAE YFWTINGKFQ QSGQKLSIPQ ITTKHRGLYT CSVRNSATGK ESSKSMTVEV SAPSGIGRLP LLNPI
Explore Pregnancy-specific beta-1-glycoprotein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets